Skip to main content

Table 5 Relative risk of second primary cancer by type of first primary cancer and follow-up interval, Queensland, 1982-2006

From: The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study

  Follow-up interval
  2 months to less than 1 year 1 year to less than 5 years 5 years to less than 10 years 10 years or longer
First primary cancer Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
   Head and neck 164 1.67
(1.42-1.95)
731 2.00
(1.86-2.15)
651 2.10
(1.94-2.26)
443 1.89
(1.72-2.08)
   Oesophagus 22 1.22
(0.77-1.85)
42 1.31
(0.95-1.77)
32 1.76
(1.20-2.48)
9 1.11
(0.51-2.10)
   Stomach 36 0.97
(0.68-1.35)
75 0.95
(0.74-1.18)
55 1.04
(0.78-1.35)
40 0.99
(0.71-1.35)
   Colorectal 310 1.03
(0.92-1.16)
1,131 1.07
(1.01-1.13)
912 1.11
(1.04-1.18)
693 1.14
(1.06-1.23)
   Pancreas 14 0.74
(0.40-1.24)
20 1.01
(0.62-1.57)
15 0.99
(0.55-1.64)
-- --
   Lung 147 1.06
(0.89-1.24)
312 1.46
(1.30-1.63)
183 1.71
(1.47-1.98)
87 1.35
(1.08-1.67)
   Melanoma 458 2.15
(1.95-2.35)
1,798 1.92
(1.84-2.02)
1,553 1.80
(1.71-1.89)
1,283 1.63
(1.55-1.73)
   Breast - female 194 1.02
(0.88-1.18)
1,020 1.25
(1.17-1.33)
1,019 1.44
(1.35-1.53)
729 1.36
(1.26-1.46)
   Cervix 33 2.13
(1.46-2.99)
89 1.46
(1.18-1.80)
89 1.43
(1.15-1.76)
89 1.09
(0.87-1.34)
   Uterus 29 1.03
(0.69-1.48)
134 1.15
(0.96-1.36)
147 1.36
(1.15-1.60)
99 1.00
(0.81-1.21)
   Ovary 22 1.22
(0.77-1.85)
54 1.04
(0.78-1.35)
46 1.18
(0.86-1.57)
42 1.11
(0.80-1.50)
   Prostate 344 0.81
(0.73-0.90)
1,368 0.84
(0.80-0.89)
988 0.88
(0.82-0.93)
306 0.66
(0.59-0.74)
   Kidney 115 2.45
(2.02-2.94)
254 1.57
(1.38-1.77)
177 1.42
(1.22-1.65)
109 1.35
(1.11-1.63)
   Bladder 249 2.40
(2.11-2.72)
668 1.73
(1.61-1.87)
477 1.61
(1.47-1.76)
286 1.39
(1.23-1.56)
   Brain & CNS 6 0.60
(0.22-1.31)
12 0.77
(0.40-1.34)
18 1.44
(0.85-2.28)
14 1.28
(0.70-2.15)
   Thyroid 18 1.65
(0.98-2.61)
78 1.53
(1.21-1.91)
63 1.21
(0.93-1.55)
56 1.16
(0.87-1.50)
   Non-Hodgkin lymphoma 74 1.23
(0.97-1.55)
262 1.31
(1.16-1.48)
209 1.46
(1.27-1.67)
144 1.49
(1.26-1.76)
   Lymphoid leukaemia 52 1.82
(1.36-2.39)
156 1.40
(1.19-1.64)
143 1.89
(1.59-2.23)
71 1.78
(1.37-2.22)
   Myeloid leukaemia 27 1.59
(1.05-2.31)
57 1.44
(1.09-1.87)
28 1.40
(0.93-2.03)
13 1.41
(0.75-2.41)
   Myeloma/PCT 18 0.76
(0.45-1.21)
68 1.02
(0.79-1.29)
36 1.26
(0.88-1.74)
12 1.12
(0.58-1.95)
   Other 179 1.22
(1.05-1.42)
595 1.35
(1.25-1.47)
447 1.36
(1.24-1.49)
332 1.33
(1.19-1.48)
   All cancers combined 2,511 1.32
(1.27-1.37)
8,924 1.33
(1.31-1.36)
7,286 1.39
(1.35-1.42)
4,859 1.28
(1.24-1.31)
  1. Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma cell tumours. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. SIRs for pancreatic cancer for 5 years to less than 10 years after first diagnosis and 10 years or longer after first diagnosis have been combined due to less than 5 observed cases 10 years or longer after first diagnosis.